Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia
- 1 July 2002
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 30 (1) , 9-13
- https://doi.org/10.1038/sj.bmt.1703589
Abstract
This multicenter study was designed to evaluate whether allo-PBPCT provides some advantages, if any, over BMT in terms of engraftment kinetics, acute and chronic GVHD incidence, TRM, relapse incidence and survival in acute lymphoblastic leukemia patients (ALL). From January 1995 to December 1999, 67 ALL patients (34 in the PBPCT group and 33 in the BMT group) were included in this study. Median age for both groups was 8 years (range, 1-18). There were 24 patients in first or second CR in the PBPCT group and 28 such patients in the BMT group. Preparatory regimens were TBI-based in 26/34 in the PBPC group and 25/33 in the BMT group. GVHD prophylaxis was CsA alone in 38 patients (18 PBPCT vs 20 BMT) and CsA plus short Mtx in 29 (16 PBPCT vs 13 BMT). Engraftment was achieved in all cases. Median days to neutrophil recovery was 10 (range, 7-18) after PBPCT vs 14 (range, 9-21) after BMT (P < 0.0001). Platelet engraftment (>50 x 10(9)/l) was also faster for PBPCT patients (median 13 days, range, 9-40 vs 23 days, range, 15-165) (P < 0.0001). Acute GVHD grade II-IV incidence was similar in both groups (46.4 +/- 8.8% vs 42.7 +/- 8.6%) (P = 0.45). Probability of chronic GVHD was 50.6 +/- 12.2% after PBPCT vs 27.8 +/- 9.2% after BMT (P = 0.1). Probability of relapse was similar (28.7 +/- 9.2% for PBPCT vs 27.1 +/- 8.2% for BMT) (P = 0.89). There were eight patients who died from transplant-related complications after PBPCT vs 5 after BMT (P, NS). With a median follow-up of 25 months the event-free survival probability was 53 +/- 8.9% for PBPCT vs 54.9 +/- 9.7% for BMT (P = 0.54). Using PBPC for allogeneic transplantation in childhood ALL results in faster hematopoietic recovery compared to BM, with a similar incidence of aGVHD, TRM, relapse and disease-free survival. However, the issue of cGVHD remains unresolved.Keywords
This publication has 25 references indexed in Scilit:
- Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor RegistryBone Marrow Transplantation, 1999
- Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donorsBone Marrow Transplantation, 1999
- Total body irradiation–high‐dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA‐identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle studyBritish Journal of Haematology, 1998
- Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experienceBritish Journal of Haematology, 1998
- Allogeneic peripheral blood stem cell transplant in childrenMedical and Pediatric Oncology, 1998
- Allogeneic blood stem cell transplantation in advanced hematologic cancersBone Marrow Transplantation, 1997
- Transplantation of peripheral blood progenitor cells from HLA‐identical sibling donorsBritish Journal of Haematology, 1996
- Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second RemissionNew England Journal of Medicine, 1994
- Allogeneic Bone Marrow Transplantation after Hyperfractionated Total-Body Irradiation and Cyclophosphamide in Children with Acute LeukemiaNew England Journal of Medicine, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958